ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 50
- Registration Number
- NCT01644396
- Locations
- 🇷🇺
Site Reference ID/Investigator# 67545, St. Petersburg, Russian Federation
🇷🇺Site Reference ID/Investigator# 67547, Ekaterinburg, Russian Federation
🇷🇺Site Reference ID/Investigator# 78417, Smolensk, Russian Federation
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Biological: adalimumab
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 508
- Registration Number
- NCT01635764
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 872
- Registration Number
- NCT01620528
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 12
- Registration Number
- NCT01617928
- Locations
- 🇯🇵
Site Reference ID/Investigator# 68622, Tokyo, Japan
A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 32
- Registration Number
- NCT01609933
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT01594229
- Locations
- 🇺🇸
Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States
🇺🇸Emory University Hospital /ID# 67349, Atlanta, Georgia, United States
🇺🇸Georgia Regents University /ID# 67342, Augusta, Georgia, United States
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Neuropathic Pain
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 39
- Registration Number
- NCT01589432
- Locations
- 🇬🇧
Site Reference ID/Investigator# 68882, London, United Kingdom
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 32
- Registration Number
- NCT01589419
- Locations
- 🇺🇸
Site Reference ID/Investigator# 99095, Scottsdale, Arizona, United States
🇺🇸Site Reference ID/Investigator# 68045, Durham, North Carolina, United States
🇦🇺Site Reference ID/Investigator# 67882, East Melbourne, Australia
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
- Conditions
- Diabetic Neuropathic Pain
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 1
- Registration Number
- NCT01579279
- Locations
- 🇺🇸
Site Reference ID/Investigator# 63710, Milford, Connecticut, United States
🇺🇸Site Reference ID/Investigator# 62887, Anaheim, California, United States
🇺🇸Site Reference ID/Investigator# 62884, DeLand, Florida, United States
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: BI 655066 (very high i.v. dose)Drug: Placebo, i.v.Drug: Placebo, s.c.Drug: BI 655066 (high s.c. dose)Drug: BI 655066 (low i.v. dose)Drug: BI 655066 (low s.c. dose)Drug: BI 655066 (high medium i.v. dose)Drug: BI 655066 (very low i.v. dose)Drug: BI 655066 (high i.v. dose)Drug: BI 655066 (low medium i.v. dose)
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 39
- Registration Number
- NCT01577550
- Locations
- 🇺🇸
1311.1.0007 Boehringer Ingelheim Investigational Site, Burbank, California, United States
🇩🇪1311.1.4901 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇸1311.1.0003 Boehringer Ingelheim Investigational Site, Port Orange, Florida, United States